24 December 2015 - NICE is reviewing its guidance on ezetimibe (Ezetrol, MSD) for adults with primary (heterozygous-familial and non-familial) hypercholesterolaemia. Following comments received during consultation on its previous draft guidance, NICE has today published revised draft guidance that in essence reverts to the guidance being reviewed.

For more details, go to: http://www.nice.org.uk/news/press-and-media/nice-issues-revised-draft-guidance-on-ezetimibe-for-hypercholesterolaemia